260978-31-2

Upstream product

• 67-56-1 methanol 
• 260978-83-4 (4S,5S)-4-[(1R,4R,2E)-1-(tert-Butoxycarbonylamino)-4-benzyloxymethoxypent-2-enyl]-5-(tert-butyldimethylsilyloxymethyl)-2,2-dimethyl-1,3-dioxolane 
• 154674-74-5 3-O-(4-Methoxybenzyl)-4-[(1R,4R,2E)-4-benzyloxycarbonylamino-4-benzyloxymethoxypent-2-enyl]-1,2-O-isopropylidene-α-D-erythrofuranose 
• 3587-60-8 Benzyloxymethyl chloride 
• 17392-83-5 (R)-Methyl lactate 
• 260978-24-3 (E)-(1S,4R)-4-Benzyloxymethoxy-1-isopropyl-pent-2-enylamine 
• 260978-22-1 (2R,5S,3E)-2-(Benzyloxymethoxy)-6-methyl-5-(2,2,2-trifluoroacetylamino)hept-3-ene 
• 260978-20-9 (2R,3S,4E)-2-(Benzyloxymethoxy)-6-methyl-3-(2,2,2-trifluoroacetimidoyl)hept-4-ene 
• 260978-18-5 (2R,3S,4E)-2-(Benzyloxymethoxy)-6-methylhept-4-en-3-ol 
• 260978-16-3 (2R,4E)-2-(Benzyloxymethoxy)-6-methylhept-4-en-3-one 
• 154674-77-8 2-Methylpropyl (R)-2-(benzyloxymethoxy)propanoate 
• 96823-34-6 Dimethyl [(3R)-3-benzyloxymethoxy-2-oxobutyl]phosphonate 

Downstream Products

• 159572-27-7 (R)-2-((benzyloxy)methoxy)propanal 
• 220018-17-7 (2R,3R)-2-Benzyloxymethoxy-pentan-3-ol 

Relevant academic research and scientific papers

Application of 3'-hydroxyitraconazole

The invention discloses an application of 3'-hydroxyitraconazole, and in particular discloses an application of the 3'-hydroxyitraconazole in preparation of a medicine for reducing mTOR signal transduction activity. The 3'-hydroxyitraconazole can reduce the mTOR signal transduction activity, and can be used for treating or preventing cell proliferation diseases, treating and preventing cancers, preventing or regulating cancer cells and cancer metastasis, and treating or preventing rheumatoid arthritis, retinopathy, maculopathy, skin diseases and lupus erythematosus.

Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]

As part of a detailed study, the syntheses, biological activities, and pharmacokinetic properties of hydroxylated analogues of the previously described broad spectrum antifungal agents, Sch 51048 (1), Sch 50001 (3), and Sch 50002 (4), are described. Based on an overall superior profile, one of the alcohols, Sch 56592 (2), was selected for clinical studies.

Stereoselective synthesis of allylic amines by rearrangement of allylic trifluoroacetimidates: Stereoselective synthesis of polyoxamic acid and derivatives of other α-amino acids

On heating in xylene under reflux, allylic trifluoroacetimidates undergo [3,3] sigmatropic rearrangement to regioisomeric allylic trifluoroacetamides. Examples include the rearrangements of the trifluoroacetimidates 16 and 73 to the trifluoroacetamides 17 and 74, which were incorporated into stereoselective syntheses of polyoxamic acid 1, and the rearrangement of the trifluoroacetimidate 26. The rearrangement was the key step in asymmetric syntheses of the (S)- and (R)-valine derivatives 37 and 48. Other examples include rearrangements of the trifluoroacetimidates 52, 54 and 56 prepared from geraniol, cinnamyl alcohol and sorbyl alcohol, respectively, and the more complex trifluoroacetimidates 62 and 69. The stereoselectivity of these rearrangements, which are somewhat faster than rearrangements of analogous allylic trichloroacetimidates, is consistent with the participation of chair-like, six-membered, transition structures. The Royal Society of Chemistry 1999.

Stereoselective synthesis of thymine polyoxin C using an allylic trifluoroacetimidate-trifluoroacetamide rearrangement

A stereoselective synthesis of thymine polyoxin C 3 is described in which the key step is the [3,3] sigmatropic rearrangement of the trifluoroacetimidate 12 to the trifluoroacetamide 13. Exchange of the protecting groups followed by ozonolysis and further oxidation then gave the methyl ester 20 which was converted into thymine polyoxin C 3 by introduction of the pyrimidine followed by final deprotection. The Royal Society of Chemistry 1999.